Bcl-x and the regulation of survival in the immune system

Immunologic Research

Volumn 16, Issue 2, 1997, Pages 149-160

  Behrens, Timothy W ^a   Mueller, Daniel L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; B lymphocyte; Bcl x; Immunity; T lymphocyte

Indexed keywords

APOPTOSIS; ARTICLE; B LYMPHOCYTE; EXPERIMENTAL MODEL; IMMUNE SYSTEM; IMMUNOREGULATION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030787798     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02786359     Document Type: Article

References (72)

1. Cohen JJ, Duke RC, Fadok VA, Sellins KS: Apoptosis and programmed cell death in immunity. Ann Rev Immunol 1992; 10:267-293.
2. King LB, Ashwell JD: Signaling for death of lymphoid cells. Curr Opin Immunol 1993;5:368-373.
3. Schwartz LM, Osborne BA: Programmed cell death, apoptosis and killer genes. Immunology Today 1993;14:582-590.
4. Nossal GJV: Negative selection of lymphocytes. Cell 1994;76:229-239.
5. Krammer PH, Behrmann I, Daniel P, Dhein J, Debatin K-M: Regulation of apoptosis in the immune system. Curr Opinion Immunol 1994;6:279-289.
6. Green DR, Scott DW: Activation-induced apoptosis in lymphocytes. Curr Opinion Immunol 1994;6: 476-487.
7. Nagata S, Golstein P: The Fas death factor. Science 1995;267: 1449-1456.
8. Sprent J: T and B memory cells. Cell 1994;76:315-322.
9. Lenardo MJ: Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 1991;353:858-861.
10. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-243.
11. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li WM, Richards S, Dhein J, Trauth BC, et al.: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992;267: 10, 709-10, 715.
12. Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR: Role for c-Myc in activation-induced apoptotic cell death in T cell hybridomas. Science 1992; 257:212-214.
13. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-852.
14. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-849.
15. Woronicz JD, Calnan B, Ngo V, Winoto A: Requirement for the orphan steroid receptor nur77 in apoptosis of T-cell hybridomas. Nature 1994;367:277-281.
16. Liu Z-G, Smith SW, McLaughlin KA, Schwartz LM, Osborne BA: Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77. Nature 1994; 367:281-284.
17. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14:18) chromosome translocation. Science 1984;226:1097-1099.
18. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ: Cloning the chromosomal breakpoint of t(14:18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985;41:889-906.
19. Cleary ML, Sklar J: Nucleotide sequence of a t(14:18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985;82:7439-7443.
20. Korsmeyer SJ: Bcl-2:an antidote to programmed cell death. Cancer Surv 1992;15:105-118.
21. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
22. Reed JC, Miyashita T, Cuddy M, Cho D: Regulation of p26-bcl-2 protein levels in human peripheral blood lymphocytes. Lab Invest 1992;67:443-449.
23. Veis DJ, Sentman CL, Bach EA, Korsmeyer SJ: Expression of the Bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes. J Immunol 1993; 151:2546-2554.
24. Merino R, Ding L, Veis DJ, Korsmeyer SJ, Nunez G: Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 1994; 13:683-691.
25. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ: Bcl-2 deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993;75:229-240.
26. Nakayama KI, Nakayama K, Negishi I, Kuida K, Shinkai Y, Louie MC, Fields LE, Lucas PJ, Stewart V, Alt FW, Loh DY: Disappearance of the lymphoid system in bcl-2 homozygous mutant chimeric mice. Science 1993;261: 1584-1588.
27. Nakayama K-I, Nakayama K, Dustin LB, Loh DY: T-B cell interaction inhibits spontaneous apoptosis of mature lymphocytes in bcl-2 deficient mice. J Exp Med 1995;182:1101-1109.
28. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2, Proc Natl Acad Sci USA 1993;90: 3516-3520.
29. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
30. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB: Bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
31. Lin EY, Orlofsky A, Berger MS, Prystowsky MB: Characterization of Al, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol 1993;151:1979-1988.
32. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ: Bad, a heterodimeric partner for bcl-xL and bcl-2, displaces bax and promotes cell death. Cell 1995;80:285-291.
33. Kiefer MC, Brauer MJ, Powers VC, Wu JJ, Umansky SR, Tomei LD, Barr PJ: Modulation of apoptosis by the widely distributed bcl-2 homologue bak. Nature 1995;374:736-739.
34. Fang W, Rivard JJ, Mueller DL, Behrens TW: Cloning and molecular characterization of mouse bcl-x in B and T lymphocytes. J Immunol 1994;153:4388-4398.
35. Gonzalez-Garcia M, Perez-Ballestero R, Ding L, Duan L, Boise LH, Thompson CB, Nunez G: Bcl-xL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development, 1994; 120:3033-3042.
36. Jaattela M, Benedict M, Tewari M, Shayman JA, Dixit VM: Bcl-x and bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A(2) in breast carcinoma cells. Oncogene 1995;10: 2297-2305.
37. Minn AJ, Rudin CM, Boise LH, Thompson CB: Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 1995;86: 1903-1910.
38. Choi M, Boise LH, Gottschalk AR, Quintans J, Thompson CB, Klaus GGB: The role of bcl-x(L) in CD40-mediated rescue from anti-mu-induced apoptosis in WEHI-231 B lymphoma cells. Eur J Immunol 1995;25:1352-1357.
39. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nunez G, Castle VP: Bcl-x(l) is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 1995;55:2576-2582.
40. Fang W, Rivard JJ, Ganser JA, LeBien TW, Nath KA, Mueller DL, Behrens TW: Bcl-xL rescues WEHI 231 B lymphocytes from oxidant-mediated death following diverse apoptotic stimuli. J Immunol 1995;155:66-75.
41. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S, Loh DY: Massive cell death of immature hematopoietic cells and neurons in bcl-x-deficient mice. Science 1995;267: 1506-1510.
42. Minn AJ, Boise LH, Thompson CB: Bcl-xS antaganizes the protective effects of bcl-xl. J Biol Chem 1996;271:6306-6312.
43. Evan DL, Mansel RE: Molecular evolution and secondary structural conservation in the B-cell lymphoma and leukemia 2 (bcl-2) family of proto-oncogene products. J Mol Evol 1995;41:775-783.
44. Chen-Levy Z, Cleary ML: Membrane topology of the bcl-2 protooncogenic protein demonstrated in vitro. J Biol Chem 1990;265: 4929-4933.
45. Nguyen M, Millar DG, Yong VW, Korsmeyer SJ, Shore GC: Targeting of bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J Biol Chem 1993;268:25,265-25,268.
46. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990. 348:334-336.
47. Jacobson MD, JF Burne, MP King, T Miyashita, JC Reed, and MC Raff, Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA Nature 1993;361:365-369.
48. Lithgow T, vanDriel R, Bertram JF, Strasser A: The protein product of the oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and the outer mitochondrial membrane. Cell Growth Different 1994;5:411-417.
49. Scott DW, Tuttle J, Livnat D, Haynes W, Cogswell J, Keng P: Lymphoma models for B-cell activation and tolerance. II Growth inhibition by anti-mu of WEHI-231 and the selection of properties of resistant mutants. Cell Immunol 1985;93:124-132.
50. Benhamou LE, Cazenave PA, Sarthou P: Anti-immunoglobulins induce death by apoptosis in WEHI-231 B lymphoma cells. Eur J Immunol 1990;20:1405-1407.
51. Hasbold J, GG Klaus: Antiimmunoglobulin antibodies induce apoptosis in immature B cell lymphomas. Eur J Immunol 1990;20: 1685-1690.
52. Merino R, Grillot DAM, Simonian PL, Muthukkumar S, Fanslow WC, Bondada S, Nunez G: Modulation of anti-IgM-induced B cell apoptosis by bcl-xL and CD40 in WEHI-231 cells. J Immunol 1995; 155:3830-3838.
53. Ishida T, Kobayashi N, Tojo T, Ishida S, Yamamoto T, Inoue J: CD40 signaling-mediated induction of bcl-xL, Cdk4, and Cdk6. J Immunol 1995;155:5527-5535.
54. Grillot DAM, Merino R, Pena JC, Fanslow WC, Finkelman FD, Thompson CB, Nunez G: Bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J Exp Med 1996;183:381-391.
55. Choi MSK, Holman M, Atkins CJ, Klaus GGB: Expression of bcl-x during mouse B cell differentiation and following activation by various stimuli. Eur J Immunol 1996;26:676-682.
56. Fang W, Nath KA, Mackey MF, Noelle RJ, Mueller DL, Behrens TW: CD40 inhibits B cell apoptosis by upregulating bcl-xL expression and blocking oxidant accumulation. Am J Physiol 272 (Cell Physiol): 1997;C950-C956.
57. Marshall LS, Aruffo A, Ledbetter JA, Noelle RJ: The molecular basis for T cell help in humoral immunity: CD40 and its ligand, gp39. J Clin Immunol 1993;13: 165-174.
58. Bancereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S: The CD40 antigen and its ligand. Annu Rev Immunol 1994;12:881-922.
59. Fang W, Mueller DL, Pennell CA, Rivard JJ, Li Y-S, Hardy RR, Schlissel M, Behrens TW: Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. Immunity 1996;4:291-299.
60. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K: Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow, J Exp Med 1991;173:1213-1225.
61. Krajewski S, Krajewska M, Shabaik A, Wang HG, Irie S, Fong L, Reed JC: Immunohistochemical analysis of in vivo patterns of bcl-x expression. Cancer Res 1994;54: 5501-5507.
62. Grillot DAM, Merino R, Nunez G: Bcl-xL displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice. J Exp Med 1995;182:1973-1983.
63. Ma A, Pena JC, Chang B, Margosian E, Davidson L, Alt FW, Thompson CB: Bcl-x regulates survival of double positive thymocytes. Proc Natl Acad Sci USA 1995;92:4763-4767.
64. Ohta K, Iwai K, Kasahara Y, Taniguchi N, Krajewski S, Reed JC, Miyawaki T: Immunoblot analysis of cellular expression of bcl-2 family proteins, bcl-2, bax, bcl-x and mcl-1, in human peripheral blood and lymphoid tissues. Int Immunol 1995;7:1817-1825.
65. Gratiot-Deans, J, L Ding, LA Turka, and G Nunez, Bcl-2 protooncogene expression during human T cell development. J Immunol 1993;151:83-91.
66. Gratiot-Deans J, Merino R, Nunez G, Turka L: Bcl-2 expression during T-cell development: Early loss and late return occur at specific stages of commitment to differentiation and survival. Proc Natl Acad Sci USA 1994;91:10,685-10,689.
67. Linette GP, Grusby JJ, Hedrick SM, Hansen TH, Glimcher LH, Korsmeyer SJ: Bcl-2 is upregulated at the CD4+CD8+ stage during positive selection and promotes thymocyte differentiation at several control points. Immunity, 1994;197-205.
68. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ: Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991;67:879-888.
69. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Linsten TL, Thompson CB: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL Immunity 1995;3: 87-98.
70. Mueller DL, Fang W, Behrens TW: Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells: A model for long-term survival of memory T cells. J Immunol 1996;156: 1764-1771.
71. Broome HE, Dargan CM, Krajewski S, Reed JC: Expression of Bcl-2, Bcl-x and Bax after T cell activation and IL-2 withdrawal. J lmmunol 1995;155:2311-2317.
72. Sperling AI, Auger JA, Ehst BD, Rulifson IC, Thompson CB, Bluestone JA: CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J Immunol 1996;157: 3909-3917.